Guinea to Expand Use of Experimental Anti-Ebola Drugs

Guinea's government has authorized the wider use of an experimental drug to treat Ebola in treatment centers after successful initial trials, officials said

Join Our Community of Science Lovers!

CONAKRY (Reuters) - Guinea's government has authorized the wider use of an experimental drug to treat Ebola in treatment centers after successful initial trials, officials said on Saturday.

The expansion of the treatment comes as the number of people with Ebola in Guinea has doubled in the past week, reversing a broader trend of decline across the three worst-hit West African states - Guinea, Liberia and Sierra Leone.

The experimental Japanese drug - Avigan, or favipiravir - developed by Toyama Chemical, a subsidiary of Japan's Fujifilm, has been tested by French and Guinean teams in southern Guinea since mid-December.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


French President Francois Hollande's office said on Wednesday that the results had been positive and the drug appeared to accelerated the recovery process of patients.

"We have decided to broaden the use of this drug. It will only be available in the Ebola Treatment Units, not the hospitals," Sakoba Keita, coordinator of Guinea's Ebola response, told reporters on Saturday.

Guinea's anti-Ebola task force said about two dozen new cases of Ebola had been recorded in the last two weeks, taking the total number to 53 as of Friday. Officials are accessing villages where they had previously faced local resistance to their presence.

Health officials have not provided any data for the results of the trials of the anti-Ebola drug.

Keita said that after testing in Gueckedou and Nzerekore, favipiravir has been distributed to the town of Coyah and talks are underway start treatment in the capital, Conakry.

"We are looking to see how we can get it to other parts of the country too," he said.

The epidemic has killed nearly 9,000 people over the last year, mainly in the three worst-affected West African nations.

Guinea, where the outbreak began, has recorded over 1,900 dead from some 3,000 confirmed cases.

"The Ebola situation is getting better but we are not cured," said Jean-François Delfraissy, a French Ebola expert working alongside Guinean authorities to contain the crisis.

 

(Reporting by Saliou Samb. Writing by David Lewis, editing by Mike Peacock)

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe